High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification.
Source check: Source checked. Not independent scientific confirmation.
Finding: The primary Results and Experimental Procedures show image-derived multivariate phenotypes and classifiers separated LRRK2-mutant from isogenic control dopaminergic neurons and detected compound effects, with a second SNCA triplication model used for validation.
Technology: Results and Experimental Procedures show image-derived multivariate phenotypes and classifiers separated LRRK2-mutant from isogenic control dopaminergic neurons and detected compound effects, with a second SNCA triplication model used for validation.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Results and Experimental Procedures show image-derived multivariate phenotypes and classifiers separated LRRK2-mutant from isogenic control dopaminergic neurons and detected compound effects, with a second SNCA triplication model used for validation.
- Test and result
- LDA, SVM and LightGBM used quantitative image features; the paper applied the trained classifier to independent SNCA-triplication neurons and to treated versus DMSO neurons.
- Limitation / still unknown
- The isogenic and second-model comparisons support in-vitro disease-model phenotyping; this does not establish patient benefit or a new clinical therapy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9561636/ · https://europepmc.org/article/MED/36179692 · https://pmc.ncbi.nlm.nih.gov/articles/PMC9561636/#Results:
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.